Mildronate (Meldonium Dihydrate)

Meldonium, the active ingredient in Mildronate, is a metabolic modulator presented as an oral tablet formulation for oral use. It is employed in the management of ischemic heart disease, angina pectoris and heart failure, helping to improve cardiac energy metabolism in adult patients.

GNH USA supplies Mildronate as a licensed, Good Distribution Practice‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide under strict quality assurance protocols. The company adheres to regulatory standards across EU and other markets, ensuring consistent batch release and traceability.

Mildronate is used to address cardiovascular conditions related to impaired myocardial energy metabolism.

- Ischemic heart disease: improves myocardial energy efficiency and reduces symptoms. - Angina pectoris: alleviates chest pain by enhancing cardiac metabolism. - Heart failure: supports cardiac function by shifting energy substrate utilization.

Mildronate may be associated with several adverse reactions, which can vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate. - Nausea: occasional upset stomach. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Allergic reactions: rash, pruritus, or anaphylaxis. - Hepatotoxicity: elevated liver enzymes. - Cardiac arrhythmias: rare irregular heartbeat.

When prescribing Mildronate, clinicians should consider several precautionary measures to ensure safe use. - Cardiovascular assessment: evaluate patient’s cardiac status before initiation. - Renal function: monitor renal function in patients with impairment. - Hepatic function: assess liver enzymes periodically. - Concomitant medications: review for drugs affecting carnitine metabolism. - Pregnancy and lactation: avoid use unless benefits outweigh risks. - Store at ambient temperature: keep tablets in original packaging, protect from moisture and heat.

Mildronate can interact with other medicines, requiring attention to potential pharmacodynamic or pharmacokinetic effects.

Major Interactions (Avoid): - Carnitine supplements: may counteract the drug’s mechanism. - Beta‑blockers: combined effect on heart rate may be excessive.

Moderate Interactions (Monitor Closely): - Antihypertensives: may enhance blood pressure lowering. - Statins: possible increased risk of muscle toxicity. - Diuretics: monitor electrolyte balance.